JPMorgan Starts Kura Oncology (KURA) at Overweight
JPMorgan analyst Priyanka Grover initiates coverage on Kura Oncology (NASDAQ: KURA) with a Overweight rating and a price target of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)

